Welcome to our dedicated page for SL Science Holding news (Ticker: SLBT), a resource for investors and traders seeking the latest updates and insights on SL Science Holding stock.
The SLBT news page on Stock Titan focuses on developments related to SL Science Holding Limited and its connection to SL BIO Ltd. and Horizon Space Acquisition II Corp. SLBT is expected to be the ticker symbol for SL Science Holding Limited, the post-business combination holding company for SL BIO Ltd., a biomedical company that concentrates on cellular and gene therapies for regenerative medicine and cancer treatment.
News for SLBT will center on the progress of the proposed business combination between SL BIO Ltd. and Horizon Space Acquisition II Corp., a special purpose acquisition company (SPAC). Coverage includes milestones such as the effectiveness of the registration statement on Form F-4 with the U.S. Securities and Exchange Commission, scheduling and outcomes of shareholder meetings, and satisfaction of listing and closing conditions for the Nasdaq listing under the SLBT symbol.
Because SL BIO Ltd. operates in the biopharmaceutical space, SLBT-related news may also feature updates on its cellular and gene therapy programs, including work with immune stem cells, Armed-T and Gamma Delta T cell technologies, and bovine-derived milk exosome applications in tissue regeneration, skincare, and cancer recovery, when such information is disclosed in official communications.
Investors and observers can use this page to follow regulatory announcements, transaction-related disclosures, and corporate communications tied to the SPAC combination and the anticipated Nasdaq listing. Bookmark this feed to review new press releases and other news items as they are published through recognized newswire and disclosure channels.
SL Science Holding Limited (SLBT) rang the Nasdaq opening bell at MarketSite in New York to mark its first quarter as a publicly traded company, following its June 15, 2026 listing after a business combination with Horizon Space Acquisition II Corp.
During this eleven-week period, the company advanced its γδ T cell platform, highlighted by an ongoing Orphan Drug Designation request for Vdelta2+ γδT cells in glioblastoma multiforme under FDA review since March 2026, for which additional nonclinical data are being prepared. Preclinical intracranial γδT cell therapy data in glioblastoma models were exhibited in July 2026 at the World Congress of Basic and Clinical Pharmacology. SL Science licenses its γδT cell platform from JY BioMed for brain and pancreatic cancers and has filed FDA Drug Master Files covering γδT cells and γδT-derived exosomes to support Chemistry, Manufacturing, and Controls for future commercialization.
SL Science (NASDAQ: SLBT) reported that JY BioMed, its GDT platform licensor and IP holder, has filed a new U.S. FDA Drug Master File (DMF No. 044612) covering exosomes derived from Gamma Delta T (GDT) cells. This adds to an existing DMF on GDT cells and extends FDA-filed manufacturing and quality documentation across both the cellular and cell-free exosome formats of the same core technology.
According to SL Science, DMFs centralize confidential chemistry, manufacturing and controls (CMC) data that downstream regulatory submissions can reference, potentially reducing CMC-related bottlenecks for future programs. The company highlights published preclinical and independent studies indicating that GDT-derived exosomes can trigger tumor cell death, stimulate immune responses, act synergistically with radiotherapy, remain active in immunosuppressive tumor environments, and cross the blood-brain barrier, which it views as particularly relevant to its focus on glioblastoma and other brain cancers.
SL Science (Nasdaq: SLBT) announced the publication of a peer-reviewed article in Biomedicines, co-authored with Taipei Medical University researchers, that proposes a rigorous clinical development framework for γδ T cell therapy in glioblastoma, an aggressive adult brain cancer. The paper goes beyond literature review to specify clinical trial designs, biological measurements, and testing conditions needed to evaluate γδ T cell therapies in future human studies.
The framework emphasizes quantitative cell-tracking, serial pharmacodynamic sampling, and potency testing under realistic low-oxygen, low-glucose tumor conditions. It also supports direct, repeated delivery into the tumor cavity to address the blood-brain barrier and recommends focusing early trial endpoints on verifiable biological activity. According to SL Science, the publication aligns with its allogeneic, off-the-shelf γδ T cell platform and sets evidence standards for its future clinical programs, while noting that γδ T cell therapy in glioblastoma remains investigational and is not tied to any specific SL Science product.
SL Science (NASDAQ: SLBT) reported successful exhibition of joint preclinical research on a novel gamma delta (γδ) T‑cell therapy for glioblastoma at the 2026 World Congress of Basic and Clinical Pharmacology in Melbourne, held July 12‑17, 2026.
According to SL Science, investigators from Taipei Medical University, SL Science, JY BioMed and HeXun Biosciences showed that directly delivering expanded γδ T cells to tumors in preclinical GBM models led to potent tumor destruction. At the highest tested dose, using an 8:1 immune‑cell‑to‑cancer‑cell ratio, tumors were completely eradicated by day 26 post‑treatment.
The team also reported dose‑dependent tumor suppression with repeated direct‑to‑brain dosing and a favorable safety profile, with health screens and blood panels indicating no major safety concerns or adverse health effects in the study.
SL Science Holding (Nasdaq: SLBT) has submitted an Orphan Drug Designation (ODD) request to the U.S. FDA for its GDT cell therapy product Vdelta2+ Gamma Delta T Cells to treat glioblastoma multiforme (GBM). The FDA Office of Orphan Products Development has acknowledged receipt (Request No. DRU-2026-11528, received March 30, 2026) and is reviewing additional files.
The GDT platform, licensed from JY BioMed, targets tumor cells independently of MHC presentation, aiming to address tumor heterogeneity and immune evasion in solid tumors. JY BioMed will present preclinical GBM data titled “Intracranial γδ T Cell Therapy Eliminates Glioblastoma in Preclinical Models” at WCP 2026 in Melbourne, where SL Science representatives will also attend.
SL Science (Nasdaq: SLBT) reported full-year 2025 net revenue of approximately $2.20 million, down 35% year over year, with gross profit of $0.78 million and a net loss of $3.82 million.
Cash fell to $1.26 million. The company later completed a Nasdaq listing, a $7.8 million PIPE financing, and advanced its Gamma Delta T cell and CD-19 programs toward planned IND submissions in 2027.
SL Science Holding (Nasdaq: SLBT) closed its business combination with Horizon Space Acquisition II, with both now wholly owned subsidiaries of SL Science. Ordinary shares are expected to begin trading on the Nasdaq Global Market under ticker SLBT on June 15, 2026.
The deal implies an equity valuation for SL Bio of about $5.568 billion and includes a concurrent $7.8 million PIPE, supporting development of Gamma delta T cell “off-the-shelf” therapies for solid tumors and funding global expansion with an expanded executive team and independent board.
SL BIO Ltd. (expected Nasdaq: SLBT) and Horizon Space Acquisition II Corp. announced the Form F-4 registration statement in connection with their proposed business combination was declared effective by the SEC on January 13, 2026. The definitive proxy/prospectus dated January 13, 2026 began mailing to shareholders on or about that date. HSPT will hold an extraordinary general meeting at 9:00 a.m. ET on February 3, 2026 to vote on the Proposed Transactions.
Upon closing and related transactions, the post-combination holding company, SL Science Holding Limited (PubCo), is expected to list on Nasdaq under the ticker SLBT. Closing remains subject to Nasdaq listing approval, HSPT shareholder approval, and satisfaction or waiver of customary closing conditions.